13
Participants
Start Date
May 31, 2005
Primary Completion Date
January 31, 2010
Study Completion Date
April 30, 2011
Trastuzumab + Letrozole
Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
Kantonspital Aarau, Aarau
Kantonsspital Baden, Baden
Saint Claraspital AG, Basel
Universitaetsspital-Basel, Basel
Inselspital Bern, Bern
Kantonsspital Bruderholz, Bruderholz
Kantonsspital Graubuenden, Chur
Centre Hospitalier Universitaire Vaudois, Lausanne
Kantonsspital Liestal, Liestal
Ospedale Beata Vergine, Mendrisio
Praxis Dr. Beretta, Rheinfelden
Kantonsspital - St. Gallen, Sankt Gallen
City Hospital Triemli, Zurich
UniversitaetsSpital Zuerich, Zurich
Swiss Cancer Institute
OTHER